NTRR: U.S. Cannabis Industry Maintains Unprecedented Pace of Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Insys Therapeutics (INSY) Misses Q2 EPS by 10c; DEA Quota Granted
August 6, 2015 6:52 AM EDTInsys Therapeutics (NASDAQ: INSY) reported Q2 EPS of $0.10, $0.10 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $77.6 million versus the consensus estimate of $74.06 million.
DEA Quota Granted
On August 5, 2015, Insys received a DEA Quota of 200 kg for the... More
